Reuters: Chile, Peru green-light AstraZeneca COVID-19 vaccine trials
“Chilean President Sebastian Pinera said on Wednesday the country’s health regulator had given the go-ahead for clinical trials of AstraZeneca PLC’s COVID-19 vaccine. … Also on Wednesday, Peru said Johnson & Johnson and AstraZeneca laboratories would begin trials of coronavirus vaccines in the country next week…” (Laing/Aquino, 11/4).

Wall Street Journal: AstraZeneca Expects Covid-19 Vaccine Trial Results This Year
“AstraZeneca said late-stage trials for the Covid-19 vaccine it is developing with the University of Oxford are on track to produce results ‘later this year,’ with a potential rollout soon after, subject to regulatory approval. Timing of the much-anticipated results depends on community infection rates around the world, with around 23,000 volunteers now enrolled in clinical trials of the vaccine in the U.S., the U.K., Brazil, and South Africa, the British drugmaker said Thursday as it reported third-quarter earnings. The vaccine, called AZD1222, is a front-runner in the global race for a shot that will help curb infections and deaths from the virus — and get the global economy back on its feet — as the pandemic continues to spread in many parts of the world, including the U.S. and Europe…” (Strasburg, 11/5).

Additional coverage of the AstraZeneca/Oxford experimental vaccine is available from CNBC, Financial Times, and VOA News.